Clinical data
Trade namesRinvoq
Other namesABT-494
License data
  • AU: D
  • Not recommended[1]
Routes of
By mouth
Drug classJanus kinase (JAK) inhibitor
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only) [2]
  • US: ℞-only [3]
  • EU: Rx-only [4]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding52%
MetabolismHepatic (CYP3A major, CYP2D6 minor)[6]
MetabolitesM4, an acyl glucuronide
Elimination half-life9–14[5] (6–15[6]) hours
ExcretionMainly unchanged in feces (38%) and urine (24%)[5]
  • (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
CAS Number
PubChem CID
Chemical and physical data
Molar mass380.375 g·mol−1
3D model (JSmol)
  • CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
  • InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1 checkY

Upadacitinib, sold under the brand name Rinvoq, is a Janus kinase (JAK) inhibitor medication for the treatment of moderately to severely active rheumatoid arthritis in adults where methotrexate (a drug used to treat active arthritis) did not work well or could not be tolerated.[7] It was approved for medical use in the United States and in the European Union in 2019,[7][8][4] and was developed by the biotech company AbbVie.

Common side effects include upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever.[4][3]

Upadacitinib works by blocking the action of enzymes called Janus kinases.[4] These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.[4]

  1. ^ a b "Upadacitinib (Rinvoq) Use During Pregnancy". 23 September 2019. Retrieved 17 March 2020.
  2. ^ "Rinvoq 15 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)". (emc). 1 March 2020. Retrieved 22 August 2020.
  3. ^ a b Cite error: The named reference Rinvoq FDA label was invoked but never defined (see the help page).
  4. ^ a b c d e "Rinvoq EPAR". European Medicines Agency (EMA). 16 October 2019. Retrieved 29 April 2020.
  5. ^ a b Cite error: The named reference AssessmentReport was invoked but never defined (see the help page).
  6. ^ a b Mohamed MF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA (December 2016). "Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Participants with Rheumatoid Arthritis". Clinical Pharmacokinetics. 55 (12): 1547–1558. doi:10.1007/s40262-016-0419-y. PMID 27272171. S2CID 39036534.
  7. ^ a b "Drug Trials Snapshots: Rinvoq". U.S. Food and Drug Administration (FDA). 16 August 2019. Retrieved 18 March 2020. This article incorporates text from this source, which is in the public domain.
  8. ^ "AbbVie Receives FDA Approval of RINVOQ (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis" (Press release). AbbVie. Retrieved 16 August 2019.